Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Objective
To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
Objetivo
Evaluar la seguridad y tolerabilidad de REGN10933 + REGN10987 en comparación con placebo
Principal Investigator/Investigador principal
Dr. Billie Bixby and Sairam Parthasarathy
Summary of Clinical and Study Trial
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Resumen del ensayo clínico y del estudio
Seguridad, tolerabilidad y eficacia de los anticuerpos monoclonales anti-Spike (S) SARS-CoV-2 para el tratamiento de pacientes ambulatorios adultos y pediátricos con COVID-19
Contact/Contacto
Chris Ussery (cussery@arizona.edu) and Valerie Bloss (vbloss@arizona.edu)
Protocol No./Número de protocolo
NCT04425629
Phase
I/II
Age Group/Grupo de edad
Adult
Children
Adulto
Niños
Disease Site/Sitio de la enfermedad
Location/Ubicación
Alvernon CaTS Extension at University of Arizona, 655 N. Alvernon Way STE 108, Tucson, AZ 85716
Status/Estatus
Active
Activo(a)
